Baiyunshan: Subsidiary has received the "Drug Clinical Trial Approval Notice" for the new function indication of Xuhanting Granules.

The announcement from Baiyun Mountain states that its subsidiary, Guangzhou Baiyun Mountain Qixing Pharmaceutical Co., Ltd., has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for the new indication of Xuhanting granules. Xuhanting granules have the effects of nourishing qi and yin, consolidating the surface and restraining sweating. They are used for spontaneous perspiration, night sweats, and children's night sweats caused by deficiency of qi and yin. This product is a traditional Chinese medicine compound preparation that is already on the market. This application is for adding clinical trials for children with recurrent respiratory infections.